Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.

Giltnane JM, Balko JM.

Discov Med. 2014 May;17(95):275-83.

PMID:
24882719
[PubMed - in process]
Free Article
2.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W.

Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.

PMID:
24797823
[PubMed - in process]
3.

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.

J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24.

PMID:
24663045
[PubMed - in process]
4.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA.

Clin Cancer Res. 2014 Apr 1;20(7):1757-67. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.

PMID:
24398047
[PubMed - in process]
5.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.

PMID:
24356096
[PubMed - in process]
6.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS.

J Clin Invest. 2013 Oct 1;123(10):4329-43. doi: 10.1172/JCI66764. Epub 2013 Sep 3.

PMID:
23999432
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL.

Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21.

PMID:
23966295
[PubMed - indexed for MEDLINE]
8.

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7. doi: 10.1073/pnas.1303204110. Epub 2013 Aug 12.

PMID:
23940356
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The genomic map of breast cancer: which roads lead to better targeted therapies?

Balko JM, Stricker TP, Arteaga CL.

Breast Cancer Res. 2013;15(4):209.

PMID:
23905624
[PubMed - in process]
Free PMC Article
10.

Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.

Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB.

Clin Cancer Res. 2013 Jul 1;19(13):3703-13. doi: 10.1158/1078-0432.CCR-13-0623. Epub 2013 May 22.

PMID:
23697991
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30.

PMID:
23633485
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL.

J Clin Invest. 2013 Mar 1;123(3):1348-58. doi: 10.1172/JCI65416. Epub 2013 Feb 8.

PMID:
23391723
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL.

Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9.

PMID:
22879364
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

PMID:
22683778
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.

Balko JM, Arteaga CL.

Mol Diagn Ther. 2012 Feb 1;16(1):1-6. doi: 10.2165/11597430-000000000-00000.

PMID:
22339590
[PubMed - indexed for MEDLINE]
16.

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. doi: 10.1073/pnas.1115802109. Epub 2011 Dec 16.

PMID:
22178756
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.

Oh YT, Yue P, Zhou W, Balko JM, Black EP, Owonikoko TK, Khuri FR, Sun SY.

J Biol Chem. 2012 Jan 2;287(1):257-67. doi: 10.1074/jbc.M111.304006. Epub 2011 Nov 7.

PMID:
22065586
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL.

Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. Epub 2011 Jul 20.

PMID:
22049316
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.

Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, Black EP.

Br J Cancer. 2012 Jan 3;106(1):148-56. doi: 10.1038/bjc.2011.465. Epub 2011 Nov 1.

PMID:
22045191
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Miller TW, Balko JM, Arteaga CL.

J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17. Review.

PMID:
22010023
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk